KAREN RABIN to Antineoplastic Agents
This is a "connection" page, showing publications KAREN RABIN has written about Antineoplastic Agents.
Connection Strength
0.354
-
The adolescent and young adult with cancer: state of the art-- acute leukemias. Curr Oncol Rep. 2013 Aug; 15(4):317-24.
Score: 0.090
-
Attacking remaining challenges in childhood leukemia. N Engl J Med. 2012 Apr 12; 366(15):1445-6.
Score: 0.082
-
Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
Score: 0.064
-
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv. 2023 02 14; 7(3):422-435.
Score: 0.044
-
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 05 01; 36(13):1330-1338.
Score: 0.031
-
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
Score: 0.026
-
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
Score: 0.009
-
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
Score: 0.008